Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment
Authors:
- 20 January 2000
- journal article
- case report
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 49 (2) , 177-180
Abstract
We describe the case of a fatal cerebral hemorrhage associated with a severe thrombocytopenia (4.0 × 109/l), occurring only 90 min after starting treatment with abciximab, in a patient undergoing primary percutaneous transluminal coronary angioplasty (PTCA) for an acute myocardial infarction. Cathet. Cardiovasc. Intervent. 49:177–180, 2000.Keywords
This publication has 15 references indexed in Scilit:
- Fatal alveolar hemorrhage and Abciximab (ReoProTM) therapy for acute myocardial infarctionCatheterization and Cardiovascular Diagnosis, 1998
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) TherapyCirculation, 1997
- Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary InterventionCirculation, 1995
- Mitral valve rupture following percutaneous mitral commissurotomy: existence of predictive factorsEuropean Heart Journal, 1995
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic AgentsaAnnals of the New York Academy of Sciences, 1991
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988